A Nasdaq-listed clinical-stage biotech firm developing novel therapeutics for severe bacterial infections and inflammatory conditions with a massive cash balance but significant accumulated deficit.
Investors might consider this stock for its strong balance sheet with $118.3M in cash against minimal liabilities, offering a clear runway to reach potential commercial milestones. The low debt load and significant paid-in capital of $828.4M suggest management has secured substantial funding to navigate the high-risk clinical development phase without immediate dilution.
The stock carries extreme risk due to zero revenue, a negative operating profit of -$65.4M, and a deepening accumulated deficit that threatens long-term solvency if clinical trials fail. The heavy cash burn rate of nearly $68M annually combined with no current income sources makes the company highly vulnerable to market shifts or funding gaps.
Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat severe bacterial infections and inflammatory diseases. The company operates primarily in the United States, leveraging its proprietary platform to advance drug candidates through preclinical and clinical stages. With no current revenue, the firm relies heavily on equity financing and strategic partnerships to fund its high-risk R&D pipeline.
Management has maintained a robust cash position, ending the year with $118.3M despite a net cash outflow from operations of $67.7M and a substantial loss before tax of $58.8M. The company successfully utilized non-operating income, including $5.5M in interest income and $21,000 in financing cash flow, to offset heavy R&D costs of $12.3M and SG&A expenses of $42.9M.
The biopharmaceutical industry is characterized by high capital intensity and significant regulatory hurdles, where early-stage companies often operate at a loss while developing novel drug candidates. Companies in this sector rely on successful clinical trial outcomes to generate revenue, making valuation heavily dependent on pipeline potential rather than current financial performance.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $171.2M | $199.9M | $65.4M |
| Operating Income | $-171.2M | $-199.9M | $-65.4M |
| R&D | $118.9M | $133.1M | $12.3M |
| G&A | $52.3M | $48.3M | $42.9M |
| Stock-Based Comp | $41.3M | $40.8M | $26.3M |
| D&A | $723.0K | $398.0K | — |
| Depreciation | $700.0K | $400.0K | — |
| Other OpEx | $0 | $18.6M | $10.2M |
| Non-Operating Income | $2.2M | $9.4M | $6.7M |
| Interest Income | $1.9M | $5.7M | $5.5M |
| Pre-Tax Income | $-169.0M | $-190.5M | $-58.8M |
| Income Tax | $-265.0K | $-126.0K | $0 |
| Continuing Ops | $-168.7M | $-190.4M | $-58.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-168.7M | $-190.4M | $-58.8M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-168.7M | $-190.4M | $-58.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $243.1M | $187.6M | $118.5M |
| Cash & Equivalents | $106.1M | $90.1M | $118.3M |
| Marketable Securities | $127.7M | $93.8M | $0 |
| Prepaid Expenses | $7.1M | $3.5M | $257.0K |
| Other Current Assets | $2.2M | $206.0K | $0 |
| Long-Term Assets | $34.0M | $3.2M | $0 |
| PP&E (Net) | $930.0K | — | — |
| Operating Leases | $31.6M | $2.2M | — |
| Other LT Assets | $1.5M | $974.0K | — |
| Total Assets | $277.1M | $190.8M | $118.5M |
| Current Liabilities | $24.3M | $28.4M | $5.2M |
| Accounts Payable | $3.0M | $6.8M | $247.0K |
| Current Leases | $7.2M | $10.8M | — |
| Other Current Liab | $184.0K | $739.0K | $0 |
| Long-Term Liabilities | $28.2M | $16.6M | $0 |
| LT Operating Leases | $28.2M | $16.6M | — |
| Other LT Liab | $0 | $0 | — |
| Total Liabilities | $52.6M | $45.0M | $5.2M |
| Shareholders' Equity | $224.5M | $145.8M | $113.3M |
| Paid-In Capital | $690.8M | $802.0M | $828.4M |
| Retained Earnings | $-465.8M | $-656.2M | $-715.0M |
| AOCI | $-468.0K | $-62.0K | $-135.0K |
| Total L&E | $277.1M | $190.8M | $118.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-168.7M | $-190.4M | $-58.8M |
| Non-Cash Adjustments | $37.5M | $73.3M | $23.5M |
| Working Capital Changes | $-10.9M | $-7.3M | $-32.4M |
| Cash from Operations | $-142.1M | $-124.5M | $-67.7M |
| Cash from Investing | $-80.5M | $38.0M | $95.0M |
| Cash from Financing | $127.0M | $70.5M | $21.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-95.6M | $-16.0M | $27.3M |
| Beginning Cash | $202.5M | $106.9M | $91.0M |
| Ending Cash | $106.9M | $91.0M | $118.3M |
The company currently operates as a single business segment focused on research and development, generating no product revenue yet. Financial data indicates all activities are concentrated in general and administrative functions alongside substantial research and development expenditures aimed at advancing clinical candidates.
The company faces severe profitability risks with a net loss of $58.8 million in 2024 and a massive retained earnings deficit of -$715 million. There is also substantial clinical risk as all revenue streams are future-dependent and not yet realized from any approved products. High operating expenses totaling $65.4 million pose a significant burn rate challenge given the lack of current cash inflows.
The primary advantage is the company's significant liquidity position with over $118 million in cash and equivalents, providing a long runway to fund R&D without immediate need for dilutive financing. Additionally, the firm benefits from a low current liability burden of only $5.2 million, offering operational flexibility during the clinical development phase.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.